DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) saw a large increase in short interest in July. As of July 31st, there was short interest totalling 307,100 shares, an increase of 6.3% from the July 15th total of 288,800 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily volume of 94,100 shares, the short-interest ratio is presently 3.3 days.
DBV Technologies Price Performance
Shares of DBVT traded down $0.01 during mid-day trading on Friday, hitting $0.93. The stock had a trading volume of 5,736 shares, compared to its average volume of 51,975. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $3.70. The business has a fifty day moving average price of $0.91 and a 200-day moving average price of $1.26. The firm has a market cap of $89.98 million, a P/E ratio of -1.11 and a beta of 0.68.
DBV Technologies (NASDAQ:DBVT – Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the business posted ($0.26) earnings per share. As a group, research analysts expect that DBV Technologies will post -1.22 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on DBVT
Institutional Inflows and Outflows
A hedge fund recently bought a new position in DBV Technologies stock. Cowen AND Company LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Read More
- Five stocks we like better than DBV Technologies
- Top Biotech Stocks: Exploring Innovation Opportunities
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What does consumer price index measure?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.